An Open-label, Multiple Dose Study to Assess the Steady-state Skin Concentrations and Pharmacokinetics of Vildagliptin 50 mg BID for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes.
Phase of Trial: Phase I/II
Latest Information Update: 11 Mar 2016
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 19 Dec 2008 Planned number of patients changed from 32 to 22 as reported by ClinicalTrials.gov.
- 19 Dec 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.